Business Wire Industry News

Friday, February 6, 2026

Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States

TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, Nasdaq: MSLE) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the pricing of its previously announced public offering (the “Offering”) of 4,455,445 common shares and, in lieu of common shares for certain investors, pre-funded warrants to purchase 495,049 common shares. The common shares are being sold at a price of US$10.

Thursday, February 5, 2026

Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq

TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the filing of a preliminary prospectus supplement (the “Supplement”) to its short form base shelf prospectus dated October 29, 2025 (the “Base Prospectus”), in connection with a proposed public offering of its common shares (or pre-funded warrants to purchase c

Thursday, February 5, 2026

Eurofins CDMO Alphora Joins International Consortium Project to Advance Next Generation ADC Expression Platform

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Eurofins CDMO Alphora is pleased to announce that its Canadian-based division is receiving advisory services and funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support a research and development collaboration project focused on advancing a transformative approach for next-generation ADC (antibody-drug conjugate) production to meet the growing demand for targeted therapeutics. As part of this initia

Thursday, February 5, 2026

Visby Medical Collaborates with Watchmaker Genomics to Enhance Respiratory Pathogen Detection in the At-Home Setting

SAN JOSE, Calif. & BOULDER, Colo.--(BUSINESS WIRE)-- #NGS--Visby Medical, a leading innovator in at-home PCR testing of infectious diseases, has announced a strategic collaboration with Watchmaker Genomics, a supplier of innovative products for molecular analysis, to develop next-generation diagnostic tests for respiratory pathogen detection in the at-home setting. This partnership pairs Visby Medical’s instrument-free PCR testing technology – the first and only of its kind – with Watchmaker’s experti

Thursday, February 5, 2026

Quantum Motion Expands Global Presence by Opening European Offices in Spain

SAN SEBASTIAN, Spain--(BUSINESS WIRE)-- #HPC--Quantum Motion today announced the opening of its offices in Spain, establishing a permanent base for quantum system development, integration and deployment in the European Union. The new site, which is located in the newly inaugurated nanoGUNE Quantum Tower, supports Quantum Motion’s scale-up of silicon-based quantum computing systems and strengthens the collaboration across Europe’s semiconductor, academic and industrial ecosystems. The nanoGUNE Quantum

Wednesday, February 4, 2026

enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 2:30 p.m. ET. A live webcast of the fireside chat can be accessed on the "Events and Presentations” page under the “Investors” section of the enGene website at

Monday, February 2, 2026

Alcon Debuts Groundbreaking PRECISION7 in Canada, a One-Week Replacement Contact Lens to Start and End Every Week Fresh

TORONTO--(BUSINESS WIRE)-- #AlconCanada--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the Canadian launch of PRECISION7® sphere and toric, the only one-week replacement contact lens with the revolutionary ACTIV-FLO® System2,5 that provides 16 hours of outstanding comfort and precise vision, even on day 7.1 The lenses will be commercially available in Canada in February. While nearly nine out of ten Eye Care Professionals (ECPs) believe daily

Friday, January 30, 2026

ME Therapeutics Scientific and Corporate Update

VANCOUVER, British Columbia--(BUSINESS WIRE)--ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to provide a corporate update and an outline of its strategic positioning within the rapidly emerging in vivo immune cell engineering and chimeric antigen receptor (CAR) space. ME Therapeutics continues to focus it

Thursday, January 29, 2026

Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that its subsidiary, Akos Biosciences, has licensed to TOTEC Pharma, Inc. (“TOTEC”) its US Trademark portfolio for RCANN™ and an RCANN™ design. TOTEC, an affiliate of Aries Science & Technology (“Aries”), is advancing the commercializati

Thursday, January 29, 2026

Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs

TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the appointment of Antoinette Paone as Chief Development Officer (“CDO”) and Head of Regulatory Affairs. Ms. Paone brings extensive experience leading regulatory strategy from clinical development through approval, including her work on Kalydeco and Orkambi at

Wednesday, January 28, 2026

Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 328,802 shares of common stock at a purchase price of $4.41 per share. In a concurrent private placement, t

Wednesday, January 28, 2026

Repare Announces Completion of Acquisition by XenoTherapeutics, Inc.

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) announced today the completion of the previously announced acquisition of all of the issued and outstanding common shares of the Company (the “Common Shares” and the holders of the Common Shares, the “Shareholders”) by XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly “Xeno”) a non-profit biotechnology company, by way of a statutory plan of arrangement (the “Transaction” or the “Arrangeme

Wednesday, January 28, 2026

Satellos Announces Share Consolidation in Connection with Proposed Nasdaq Listing

TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announces that the Company has completed a consolidation of its outstanding common shares (the “Common Shares”) on the basis of one post-consolidation Common Share for every 12 pre-consolidation Common Shares (the “Consolidation”). The Company believes that the Consolida

Tuesday, January 27, 2026

Indero CRO and the World Scleroderma Foundation Announce Strategic Collaboration to Advance Early Therapeutic Intervention in Systemic Sclerosis

MONTREAL--(BUSINESS WIRE)--Indero is pleased to announce a strategic collaboration with the World Scleroderma Foundation (WSF) to support WSF SHIELD platform trial, a randomized, double-blind, adaptive platform clinical trial designed to evaluate multiple investigational medicinal products (IMPs) for patients meeting VEDOSS criteria. This trial aims to intervene at the earliest stages of systemic sclerosis to improve long-term patient outcomes. This partnership brings together 2 leaders in thei

Tuesday, January 27, 2026

Announcing the 2026 I.D.E.A.L. Bioscience Employers: Turning Action into Impact

OTTAWA, Ontario--(BUSINESS WIRE)-- #biosciences--In an ever-evolving Canadian bio-economy, employers who embed inclusivity, diversity, equity, and accessibility (IDEA) into their workplace culture are seeing measurable results: more innovation, stronger productivity and a competitive edge in attracting and retaining top talent. BioTalent Canada’s 2026 I.D.E.A.L. Bioscience Employers™ have exemplified these IDEA principles into real-world business advantages. The I.D.E.A.L. Bioscience Employer Recognition Prog

Tuesday, January 27, 2026

MindWalk Applies HYFT® Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced an application of its proprietary HYFT® technology designed to identify functional adjacency - meaning different molecules can produce the same therapeutic effect even when sequence comparisons suggest they are unrelated - an emerging source of competitive, legal, and valuation risk in modern drug discovery that sequenc

Monday, January 26, 2026

Definium Therapeutics Announces New Employee Inducement Grants

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 88,850 common shares of the Company (the "Options") wit

Monday, January 26, 2026

Life Sciences Ontario Celebrates Excellence and Innovation in Life Sciences with 2026 Awards Announcement

TORONTO--(BUSINESS WIRE)--Life Sciences Ontario (LSO) proudly announces the recipients of the 2026 LSO Awards, celebrating excellence, leadership, and innovation across Ontario’s life sciences sector. Now in its 23rd year, the LSO Awards continue a long-standing tradition of recognizing outstanding individuals and organizations whose contributions have significantly advanced Ontario’s life sciences ecosystem. From visionary leaders who have shaped research commercialization and public policy, t

Monday, January 26, 2026

INOVAIT Opens Call for Applications for Image-Guided Therapy and Artificial Intelligence Projects

TORONTO--(BUSINESS WIRE)--Today, INOVAIT, Canada’s image-guided therapy and artificial intelligence network, is announcing a call for applications for the Winter 2026 Pilot Fund. The Pilot Fund is a non-dilutive funding program that supports cutting-edge research and development (R&D) projects in image-guided therapy (IGT) and artificial intelligence (AI) technologies. This Pilot Fund round will provide up to 150,000 CAD to advance promising technologies through 9- to 12-month R&D proje

Monday, January 26, 2026

Eurofins CDMO Alphora Announces Development & Implementation of AI-Powered Salt and Co-Crystal Screening Software

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Eurofins CDMO Alphora is excited to announce the development and launch of a new AI-powered software for high throughput salt and co-crystal screening – now a core component of all solid-state screening programs. Developed by Eurofins CDMO Alphora, in collaboration with a local university, this cutting-edge machine learning platform provides highly accurate predictions of salt and co-crystal formation for APIs and intermediates. This breakthrough technolog

Monday, January 26, 2026

NEUPATH HEALTH ANNOUNCES EXECUTIVE LEADERSHIP CHANGES AS PART OF PLANNED TRANSITION, PRE-ANNOUNCES STRONG 2025 RESULTS

TORONTO--(BUSINESS WIRE)--NeuPath Health Inc. (TSXV:NPTH) (NeuPath or the “Company”) today announced the timing and details for a planned leadership transition in 2026, as well as preliminary revenue and Adjusted EBITDA expectations for 2025. As part of its long-term succession planning, NeuPath’s President Stephen Lemieux will succeed Joseph Walewicz as Chief Executive Officer effective April 1, 2026. Joseph will continue his role on the Board of Directors and work closely with NeuPath’s leade

Tuesday, January 20, 2026

enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it has entered into an amendment to an amended and restated loan and security agreement (as amended, the “Loan Agreement”) with two of its subsidiaries and Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”), as agent, for up to US$125 million. Access to the additional non-dilutive capital strengthens enGene’s balance sheet

Tuesday, January 20, 2026

Nonprofit Cord Blood Council Launches to Strengthen National Public Cord Blood Banks and Advance Innovation in Transplant and Cord Blood–derived Cell Therapy

SEATTLE--(BUSINESS WIRE)--The Cord Blood Council (CBC), a new capacity building nonprofit, has launched to support the nation’s public cord blood banks. The organization develops and provides shared resources to National Cord Blood Inventory (NCBI)–funded, FDA licensed public cord blood banks and the clinicians, researchers, and patients who depend on them. The CBC was created to modernize and unify critical capabilities across the cord blood community. By coordinating expertise, infrastructure

Monday, January 19, 2026

Bioscience Association Manitoba Welcomes Role on Premier’s Business and Jobs Council Workforce Development Subcommittee

WINNIPEG, Manitoba--(BUSINESS WIRE)--Bioscience Association Manitoba (BAM) is honoured to be appointed to Manitoba’s Premier’s Business and Jobs Council and the Education, Training and Workforce Development Sub-Committee. Announced by Premier Wab Kinew, the new subcommittees reflect Manitoba’s evolving economic priorities and bring together leaders from business, labour, Indigenous organizations, and post-secondary institutions to help strengthen the province’s economy amid trade negotiations w

Friday, January 16, 2026

Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that its Shareholders (as defined below) have approved the acquisition of all of the issued and outstanding common shares of the Company (the “Common Shares” and the holders of the Common Shares, the “Shareholders”) by XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly “Xeno”) a non-profit biotechnology company, b

Thursday, January 15, 2026

Nicoya Life Sciences Announces Launch of Multichannel Benchtop SPR Instrument, Aimed to Deliver Publication-Quality, Real-time Kinetic Data to Small and Midsize Research Labs

KITCHENER, Ontario--(BUSINESS WIRE)--Nicoya Life Sciences, Inc., a leading provider of advanced biophysical characterization tools for biologics discovery and development, today announced the launch of Revo™, a label-free binding kinetics platform designed to make gold-standard surface plasmon resonance (SPR) data more accessible to a broader range of researchers. By combining the trusted precision of SPR with the simplicity and usability researchers expect from modern benchtop systems, Revo en

Thursday, January 8, 2026

Global Agri-Food Advancement Partnership (GAAP) Announces Memorandum of Understanding with 9 Mile Legacy Brewing Co. Ltd. at LGCY: Innovation Hub

SASKATOON, Saskatchewan--(BUSINESS WIRE)--The Global Agri-Food Advancement Partnership (GAAP) is pleased to announce the signing of a Memorandum of Understanding (MOU) with 9 Mile Legacy Brewing Co. Ltd. at its LGCY: Innovation Hub in Saskatoon. This strategic partnership underscores GAAP’s commitment to working with industry partners to strengthen Saskatchewan’s agri-food innovation ecosystem and expand Canada’s global leadership in biotechnology and fermentation. Through this MOU, GAAP and 9

Thursday, January 8, 2026

858 Therapeutics Announces FDA Fast Track Designation for PARG Inhibitor ETX-19477 for the Treatment of Patients with BRCA-Mutated, Platinum-Resistant Ovarian Cancer

SAN DIEGO--(BUSINESS WIRE)--858 Therapeutics, a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ETX-19477, the company’s internally discovered PARG inhibitor. The designation has been granted for the treatment of adult patients with BRCA-mutated, platinum-resistant, high-grade serous ovarian cancer (HGSOC). “Patients with platinum-resistant ovarian cancer have a poor prognosis, and treatment options rem

Wednesday, January 7, 2026

Alpha Cognition Provides 2026 Corporate Update Highlighting Strategic Priorities and 2025 Commercial Execution

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition, Inc. (the “Company”, “we”, “us” and “ours”) (NASDAQ: ACOG), a commercial-stage neuroscience company focused on advancing treatments for cognitive and neuropsychiatric disorders, today announced a corporate update outlining strategic priorities for 2026 and summarizing key accomplishments achieved in 2025. Management Commentary, Michael McFadden, Chief Executive Officer “We are pleased with the transition from the